Financial results for the period ended December 31, 2025
As filed · JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
What happened
FactJB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025. Unaudited standalone financial results for the quarter /nine months ended on December. These financial results have been approved and taken on record by the Board of Directors at its.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
RevisedIndia and CDMO business should constitute around 75% - 80% of total revenue in the mid-term
India business should continue to deliver market-beating growth; Focus on increasing chronic share to 60% in the mid to long-term
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- By end of quarter 3, you should see that business growing at high single digit. (management committed by Q3 FY27)
- the second phase of our pipeline starts getting approvals from H2 of next financial year. (management committed by H2 FY27)
Evidence
- JB Chemicals & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · FY25
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%